Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.74 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.74 |
| ▸ | AR | P10275 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | TST | Q16762 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.67 |
| ▸ | VDR | P11473 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30253339 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| SCHEMBL31602211 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| SCHEMBL15261726 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| SCHEMBL4948460 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| SCHEMBL19733279 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| SCHEMBL29504071 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| SCHEMBL18393817 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| SCHEMBL1249404 | 1.00 | ALDH1A1 (0.74) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| SCHEMBL5917213 | 0.93 | ALDH1A1 (0.72) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| SCHEMBL5917211 | 0.93 | ALDH1A1 (0.72) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025108575-A1 | METHODS OF SELECTIVE DEPROTECTION AND SYNTHESIS OF TRANSHYDRINDANE- SKELETON-BASED COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| US-20240319212-A1 | METHOD OF MEASURING THE ENDOCYTIC VITAMIN D STATUS | IMMUNDIAGNOSTIK AG (DE) | 2024-09-26 | — | — | US | claimed |
| CN-113311080-B | Joint detection method for multiple vitamin D metabolites, detection kit and application thereof | 中国医学科学院北京协和医院 | 2023-02-21 | — | — | CN | claimed |
| EP-3467510-B1 | RELEASE REAGENT FOR VITAMIN D COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-10-26 | — | — | EP | claimed |
| EP-3735591-B1 | METHOD OF MEASURING THE ENDOCYTIC VITAMIN D STATUS | IMMUNDIAGNOSTIK AG (DE) | 2022-06-15 | — | — | EP | claimed |
| US-20210072263-A1 | METHOD OF MEASURING THE ENDOCYTIC VITAMIN D STATUS | IMMUNDIAGNOSTIK AG (DE) | 2021-03-11 | — | — | US | claimed |
| EP-3735591-A1 | METHOD OF MEASURING THE ENDOCYTIC VITAMIN D STATUS | Immundiagnostik AG (DE) | 2020-11-11 | — | — | EP | claimed |
| EP-3327442-B1 | RELEASE REAGENT FOR VITAMIN D COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2020-04-01 | — | — | EP | claimed |
| US-20200072854-A1 | RELEASE REAGENT FOR VITAMIN D COMPOUNDS | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2020-03-05 | — | — | US | claimed |
| WO-2019134948-A1 | METHOD OF MEASURING THE ENDOCYTIC VITAMIN D STATUS | IMMUNDIAGNOSTIK AG (DE) | 2019-07-11 | — | — | WO | claimed |
| EP-2515913-A2 | USE OF VITAMIN D GLYCOSIDES AND SULFATES FOR TREATMENT OF DISEASE | Glycomyr Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| WO-2012058614-A1 | LC-MS SEPARATION AND DETECTION OF VITAMIN D METABOLITES | COHESIVE TECHNOLOGIES INC. (US) | 2012-05-03 | — | — | WO | claimed |
| WO-2011079249-A2 | USE OF VITAMIN D GLYCOSIDES AND SULFATES FOR TREATMENT OF DISEASE | GLYCOMYR, INC. (US) | 2011-06-30 | — | — | WO | claimed |
| US-20110152207-A1 | USE OF VITAMIN D GLYCOSIDES AND SULFATES FOR TREATMENT OF DISEASE | GOFF JESSE P | 2011-06-23 | — | — | US | claimed |
| US-20080038374-A1 | New Use | LIPOPEPTIDE AB (SE) | 2008-02-14 | — | — | US | claimed |
| EP-0587751-A1 | THERAPEUTIC COMPOSITIONS FOR OSTEOINDUCTION | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-23 | — | — | EP | claimed |
| EP-0112332-B1 | VITAMIN D GLYCOSIDES | THE GENERAL HOSPITAL CORPORATION (US) | 1993-06-16 | — | — | EP | claimed |
| WO-1992021365-A1 | THERAPEUTIC COMPOSITIONS FOR OSTEOINDUCTION | THE PROCTER & GAMBLE COMPANY (US) | 1992-12-10 | — | — | WO | claimed |
| EP-0077353-A1 | 1-HYDROXYLATION PROCESS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1983-04-27 | — | — | EP | claimed |
| WO-1982003864-A1 | 1-HYDROXYLATION PROCESS | WISCONSIN ALUMNI RES FOUND (US) | 1982-11-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152207-A1 | USE OF VITAMIN D GLYCOSIDES AND SULFATES FOR TREATMENT OF DISEASE | CYP24A1, VDR, CYP2R1 | ALDH1A1 2778/4885ALOX15 949/4885CYP3A4 193/4885 |
| US-20200072854-A1 | RELEASE REAGENT FOR VITAMIN D COMPOUNDS | GC, VDR, CYP24A1 | ALDH1A1 3082/4885ALOX15 2188/4885CYP3A4 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.